Hoe verhoudt 5GH's PS Ratio zich tot zijn concurrenten?

5GH is duur op basis van de Price-To-Sales -ratio ( 12.2 x) vergeleken met het gemiddelde van de peer ( 1.1 x).

Hoe verhoudt 5GH's PS Ratio zich tot andere bedrijven in de DE Healthcare industrie?

5GH is duur op basis van de Price-To-Sales -ratio ( 12.2 x) vergeleken met het German Healthcare -industriegemiddelde ( 0.5 x).

Wat is 5GH's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

5GH is duur op basis van de Price-To-Sales Ratio ( 12.2 x) vergeleken met de geschatte Fair Price-To-Sales Ratio ( 7.7 x).

Wat is de reële prijs van 5GH als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van 5GH te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Guardant Health (XTRA:5GH) - Aandelenkoers, Nieuws & Analyse

5GH Overzicht aandelen

A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. Meer informatie

5GH fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 23.23% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Guardant Health, Inc. Concurrenten

Fresenius Medical Care

XTRA:FME

€12.4b

SYNLAB

HMSE:SYAB

€2.5b

Fresenius SE KGaA

XTRA:FRE

€18.8b

VITA 34

XTRA:V3V

€72.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Guardant Health
Historische aandelenkoersen
Huidige aandelenkoers	US$50.22
52 Week Hoogtepunt	US$94.50
52 Week Laag	US$27.29
Bèta	0.63
11 maand verandering	0%
3 maanden verandering	0%
1 Jaar Verandering	-45.86%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-61.82%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	5GH	DE Healthcare	DE Markt
7D	0%	0.1%	-0.02%
1Y	-45.9%	17.2%	8.2%

Rendement versus industrie: 5GH presteerde slechter dan de German Healthcare -sector, die het afgelopen jaar een rendement van 17.2 % opleverde.

Rendement versus markt: 5GH presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is 5GH's price volatile compared to industry and market?
5GH volatility
5GH Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 5GH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 5GH in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	1,373	Helmy Eltoukhy	guardanthealth.com

Guardant Health, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Guardant Health zich tot de beurswaarde?
5GH fundamentele statistieken
Marktkapitalisatie	€5.05b
Inkomsten(TTM)	-€582.92m
Inkomsten(TTM)	€414.64m

12.2x

P/S-verhouding

-8.7x

Koers/Winstverhouding

Is 5GH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
5GH resultatenrekening (TTM)
Inkomsten	US$430.76m
Kosten van inkomsten	US$142.63m
Brutowinst	US$288.13m
Overige uitgaven	US$893.69m
Inkomsten	-US$605.56m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-5.91
Brutomarge	66.89%
Nettowinstmarge	-140.58%
Schuld/Eigen Vermogen Verhouding	681.7%

Hoe presteerde 5GH op de lange termijn?

Bekijk historische prestaties en vergelijking

5GH Overzicht aandelen

Beloningen

Risicoanalyse

Guardant Health, Inc. Concurrenten

XTRA:FME

€12.4b

HMSE:SYAB

€2.5b

XTRA:FRE

€18.8b

XTRA:V3V

€72.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Recent updates

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Health, Inc. Announces Management Changes

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations

Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022

First quarter 2022 earnings released: US$1.21 loss per share (vs US$1.09 loss in 1Q 2021)

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults